Replies to post #58 on Black Diamond Therapeutics Inc (BDTX)

[glens0]

Quote from another board. ($BDTX 5.10 gapping up, daily chart looks sweet)

[FACT-MASTER]

Point taken.

I think what i was trying to get at was whether BDTX-1535 will demonstrate any effectiveness against
exon 20 insertion or T790M mutations.

If i'm reading the clinical site and BDTX presentation correctly exon 20 and T790M are omitted from the NSCLC trial, however are not omitted from the GBM part.

Osimertinib appears to be ineffective on both mutations which are known to be resistant to TKIs.

https://pubmed.ncbi.nlm.nih.gov/36994936/

Other refs:

https://classic.clinicaltrials.gov/ct2/show/NCT05256290

https://investors.blackdiamondtherapeutics.com/static-files/e5782d24-154c-4d23-af99-a5c3b3b3f9e1